DFTX — Definium Therapeutics, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1813814 ·
Last close
$47.07
Market Cap
$6.25B
52W High
$49.20
52W Low
$19.33
ADV30
4,120,875
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -59,220,000 | -77,098,000 | 401,293,000 | 262,518,000 | 122,444,000 |
| Dec 2025 | 0 | — | -47,578,000 | -50,436,000 | 440,100,000 | 257,837,000 | 107,773,000 |
| Sep 2025 | 0 | — | -45,669,000 | -67,265,000 | 236,916,000 | 19,959,000 | 106,320,000 |
| Jun 2025 | 0 | — | -40,903,000 | -42,744,000 | 265,091,000 | 33,392,000 | 79,691,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,560,000
Investing CF
$-151,606,000
Financing CF
$267,269,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.04
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-582,672,000
Inventory
—
Receivables
—
ST Investments
$153,756,000
EBIT TTM
$-178,311,000
Pretax Income TTM
$-183,793,000
Interest Exp TTM
$5,482,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -166,309,000 | -183,793,000 | 440,100,000 | 107,773,000 | — | -131,560,000 |
| Dec 2024 | 0 | -103,916,000 | -108,679,000 | 302,151,000 | 60,703,000 | — | -79,129,000 |
| Dec 2023 | 0 | -93,866,000 | -95,732,000 | 124,541,000 | 46,407,000 | — | -64,365,000 |
| Dec 2022 | 0 | -66,331,000 | -56,796,000 | 169,993,000 | 19,076,000 | — | -50,139,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.51
Max Pain — expiry 2026-07-17
max pain strike: $31.00 · spot: $47.07 · call oi: 11,289 · put oi: 5,031
Expected Move to 2026-07-17:
±$5.38
(11.42%) —
implied range
$41.69 –
$52.44
· ATM straddle on $47.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ICL | ICL Group Ltd. | $6.26B | $4.85 | — |
| MOS | MOSAIC CO | $6.84B | $21.51 | — |
| AXTA | Axalta Coating Systems Ltd. | $6.96B | $32.51 | — |
| PRM | Perimeter Solutions, Inc. | $5.60B | $34.32 | — |
| NEU | NEWMARKET CORP | $7.03B | $763.91 | — |
News headlines (Yahoo Finance, 1h cache)
Leaderboard Quarterly Scorecard Webinar Q&A Summary For Thursday, July 9, 2026
2026-07-09 22:33 · Yahoo
Definium Therapeutics Announces New Employee Inducement Grants
2026-07-06 20:01 · Yahoo
Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?
2026-06-30 13:21 · Yahoo
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
2026-06-26 11:53 · Yahoo
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2026-06-25 20:15 · Yahoo
To Wall Street, psychedelics biotechs are more teammates than rivals
2026-06-24 10:56 · Yahoo
Why Definium Therapeutics (DFTX) Is Up 49.8% After DT120 Phase 3 Win And $700 Million Raise
2026-06-24 04:30 · Yahoo
Definium Therapeutics (DFTX) Posts Phase 3 Win And Plans Public Offering
2026-06-24 03:28 · Yahoo
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
2026-06-24 01:57 · Yahoo
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
2026-06-23 14:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.